Review



tofacitinib simcyp model  (Simcyp)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Simcyp tofacitinib simcyp model
    Simcyp Input Parameters for the Tofacitinib PBPK Model
    Tofacitinib Simcyp Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tofacitinib+simcyp+model/pmc07689764-101-4-5?v=Simcyp
    Average 90 stars, based on 1 article reviews
    tofacitinib simcyp model - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib"

    Article Title: Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

    Journal: Journal of Clinical Pharmacology

    doi: 10.1002/jcph.1679

    Simcyp Input Parameters for the Tofacitinib PBPK Model
    Figure Legend Snippet: Simcyp Input Parameters for the Tofacitinib PBPK Model

    Techniques Used: Binding Assay, Molecular Weight, In Vitro, Recombinant

    Arithmetic Mean (SD) Observed and Predicted Pharmacokinetics of Tofacitinib After (a) a Single Intravenous or Oral Dose in Healthy Volunteers and (b) After Multiple (14 Days) Oral Doses of Tofacitinib 15 mg Twice Daily in Healthy Volunteers
    Figure Legend Snippet: Arithmetic Mean (SD) Observed and Predicted Pharmacokinetics of Tofacitinib After (a) a Single Intravenous or Oral Dose in Healthy Volunteers and (b) After Multiple (14 Days) Oral Doses of Tofacitinib 15 mg Twice Daily in Healthy Volunteers

    Techniques Used: Drug discovery

    Observed and predicted mean (with upper and lower 95% confidence limits) plasma concentration‐versus‐time profiles of tofacitinib after (A) a single intravenous infusion of 10 mg (infusion time, 0.5 hours) and (B) a single oral dose of 10 mg. CI, confidence interval; IV, intravenous; PO, oral.
    Figure Legend Snippet: Observed and predicted mean (with upper and lower 95% confidence limits) plasma concentration‐versus‐time profiles of tofacitinib after (A) a single intravenous infusion of 10 mg (infusion time, 0.5 hours) and (B) a single oral dose of 10 mg. CI, confidence interval; IV, intravenous; PO, oral.

    Techniques Used: Clinical Proteomics, Concentration Assay

    Simcyp and Clinical Assessments for Tofacitinib as a Victim of Drug‐Drug Interactions
    Figure Legend Snippet: Simcyp and Clinical Assessments for Tofacitinib as a Victim of Drug‐Drug Interactions

    Techniques Used: Inhibition

    Simulation and Clinical Assessments for the Impact of Renal and Hepatic Impairment on Tofacitinib Pharmacokinetics
    Figure Legend Snippet: Simulation and Clinical Assessments for the Impact of Renal and Hepatic Impairment on Tofacitinib Pharmacokinetics

    Techniques Used:



    Similar Products

    tofacitinib simcyp model  (Simcyp)
    90
    Simcyp tofacitinib simcyp model
    Simcyp Input Parameters for the Tofacitinib PBPK Model
    Tofacitinib Simcyp Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tofacitinib+simcyp+model/pmc07689764-101-4-5?v=Simcyp
    Average 90 stars, based on 1 article reviews
    tofacitinib simcyp model - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Simcyp Input Parameters for the Tofacitinib PBPK Model

    Journal: Journal of Clinical Pharmacology

    Article Title: Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

    doi: 10.1002/jcph.1679

    Figure Lengend Snippet: Simcyp Input Parameters for the Tofacitinib PBPK Model

    Article Snippet: To further evaluate the tofacitinib Simcyp model in other DDI scenarios under which active renal efflux transporters may be inhibited, the hypothetical effect of complete inhibition of active renal secretion was evaluated using this model. Renal clearance attributed to passive filtration was calculated as follows: passive filtration = GFR × f u,p = 125 mL/min (7.5 L/h) × 0.61 = 4.6 L/h.

    Techniques: Binding Assay, Molecular Weight, In Vitro, Recombinant

    Arithmetic Mean (SD) Observed and Predicted Pharmacokinetics of Tofacitinib After (a) a Single Intravenous or Oral Dose in Healthy Volunteers and (b) After Multiple (14 Days) Oral Doses of Tofacitinib 15 mg Twice Daily in Healthy Volunteers

    Journal: Journal of Clinical Pharmacology

    Article Title: Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

    doi: 10.1002/jcph.1679

    Figure Lengend Snippet: Arithmetic Mean (SD) Observed and Predicted Pharmacokinetics of Tofacitinib After (a) a Single Intravenous or Oral Dose in Healthy Volunteers and (b) After Multiple (14 Days) Oral Doses of Tofacitinib 15 mg Twice Daily in Healthy Volunteers

    Article Snippet: To further evaluate the tofacitinib Simcyp model in other DDI scenarios under which active renal efflux transporters may be inhibited, the hypothetical effect of complete inhibition of active renal secretion was evaluated using this model. Renal clearance attributed to passive filtration was calculated as follows: passive filtration = GFR × f u,p = 125 mL/min (7.5 L/h) × 0.61 = 4.6 L/h.

    Techniques: Drug discovery

    Observed and predicted mean (with upper and lower 95% confidence limits) plasma concentration‐versus‐time profiles of tofacitinib after (A) a single intravenous infusion of 10 mg (infusion time, 0.5 hours) and (B) a single oral dose of 10 mg. CI, confidence interval; IV, intravenous; PO, oral.

    Journal: Journal of Clinical Pharmacology

    Article Title: Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

    doi: 10.1002/jcph.1679

    Figure Lengend Snippet: Observed and predicted mean (with upper and lower 95% confidence limits) plasma concentration‐versus‐time profiles of tofacitinib after (A) a single intravenous infusion of 10 mg (infusion time, 0.5 hours) and (B) a single oral dose of 10 mg. CI, confidence interval; IV, intravenous; PO, oral.

    Article Snippet: To further evaluate the tofacitinib Simcyp model in other DDI scenarios under which active renal efflux transporters may be inhibited, the hypothetical effect of complete inhibition of active renal secretion was evaluated using this model. Renal clearance attributed to passive filtration was calculated as follows: passive filtration = GFR × f u,p = 125 mL/min (7.5 L/h) × 0.61 = 4.6 L/h.

    Techniques: Clinical Proteomics, Concentration Assay

    Simcyp and Clinical Assessments for Tofacitinib as a Victim of Drug‐Drug Interactions

    Journal: Journal of Clinical Pharmacology

    Article Title: Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

    doi: 10.1002/jcph.1679

    Figure Lengend Snippet: Simcyp and Clinical Assessments for Tofacitinib as a Victim of Drug‐Drug Interactions

    Article Snippet: To further evaluate the tofacitinib Simcyp model in other DDI scenarios under which active renal efflux transporters may be inhibited, the hypothetical effect of complete inhibition of active renal secretion was evaluated using this model. Renal clearance attributed to passive filtration was calculated as follows: passive filtration = GFR × f u,p = 125 mL/min (7.5 L/h) × 0.61 = 4.6 L/h.

    Techniques: Inhibition

    Simulation and Clinical Assessments for the Impact of Renal and Hepatic Impairment on Tofacitinib Pharmacokinetics

    Journal: Journal of Clinical Pharmacology

    Article Title: Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

    doi: 10.1002/jcph.1679

    Figure Lengend Snippet: Simulation and Clinical Assessments for the Impact of Renal and Hepatic Impairment on Tofacitinib Pharmacokinetics

    Article Snippet: To further evaluate the tofacitinib Simcyp model in other DDI scenarios under which active renal efflux transporters may be inhibited, the hypothetical effect of complete inhibition of active renal secretion was evaluated using this model. Renal clearance attributed to passive filtration was calculated as follows: passive filtration = GFR × f u,p = 125 mL/min (7.5 L/h) × 0.61 = 4.6 L/h.

    Techniques: